Coronavirus: A third of hospital patients develop dangerous blood clots

Coronavirus Outbreak

The Muslim Times has the best collection of articles for the war against Covid 19, especially about vaccines. Suggested reading by the Muslim Times: FDA authorizes the drug remdesivir for emergency use in COVID-19 patients 

Source: BBC

By Richard Galpin

Up to 30% of patients who are seriously ill with coronavirus are developing dangerous blood clots, according to medical experts.

They say the clots, also known as thrombosis, could be contributing to the number of people dying.

Severe inflammation in the lungs – a natural response of the body to the virus – is behind their formation.

Patients worldwide are being affected by many medical complications of the virus, some of which can be fatal.

Back in March, as coronavirus was spreading across the globe, doctors started seeing far higher rates of clots in patients admitted to hospital than they would normally expect.

And there have been other surprises, including the discovery of hundreds of micro-clots in the lungs of some patients.

The virus has also increased cases of deep vein thrombosis – blood clots usually found in the leg – which can be life-threatening when fragments break off and move up the body into the lungs, blocking blood vessels.

Read further

The best of the Muslim Times’ collection for war against Covid 19:

In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.

Prime Minister Shinzo Abe says more than 30 countries have asked Japan for favipiravir (Avigan) to fight Covid 19

For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology

Kaiser Permanente launches first coronavirus vaccine trial

Corona Fear’s Cure: Chanting from the Bible and the Quran

Can You Chant from the Bible or the Quran to Bliss and Happiness?

Japanese flu drug ‘clearly effective’ in treating coronavirus, says China

Synthetic antibodies might offer a quick coronavirus treatment

The Four Possible Timelines for Life Returning to Normal

The Muslim Times Recommending Universal BCG Vaccination to Fight the Pandemic

Coronavirus: TB Vaccination Trial Started in Melbourne, Australia

The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources

All of humanity are intimate neighbors: Coronavirus proves it once again

Praise be to God for the Miracle of Our Immune System

USA: 15-minute coronavirus test is here

Does the Ordinary Soap Kill Coronavirus?

Here’s a list of disinfectants you can use against coronavirus

For the number of cases and epidemiology in each country go to: WorldOMeters

1 reply

  1. Sorrento Therapeutics and Mount Sinai Health System in New York City have joined forces to develop an antibody cocktail they hope will shield against Covid-19 infection for up to two months. The treatment, called COVI-SHIELD, is designed to be administered as often as necessary, with each dose expected to provide antiviral protection for health care and other essential workers.

    If approved by the FDA, it is anticipated that COVI-SHIELD will be offered as a prophylactic for those returning to work and as a therapeutic to those who have been exposed to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus that causes Covid-19. It can also be used for the population at large as a treatment for those who may have been exposed to the disease.

    “We’re working with pharma and biotech partners, such as Sorrento, to bring much needed therapies to the clinic,” said Erik Lium, executive vice president and chief commercial innovation officer of the Mount Sinai Health System.

    The company is now completing all investigational new drug filing requirements for the triple-antibody combination therapy and expects to commence Phase 1 trials of the drug candidate in the third quarter of 2020. If successful, it would ramp up production so it could produce millions of doses by year-end in its New Jersey and European manufacturing facilities.

    Sorrento Therapeutics says that each dose of COVI-SHIELD will deliver a cocktail of three neutralizing antibodies that together would recognize three unique regions of the SARS-CoV-2 Spike protein to ward off the disease.

    This therapy is designed to be resistant to future virus mutations and, if approved, should be made available in support of testing, tracing, vaccination and other therapeutic approaches to allow for efficient management of viral infection by protecting those most at risk for up to two months at a time.

    https://www.cnbc.com/2020/05/08/sorrento-therapeutics-mount-sinai-develop-covid-19-antibody-shield.html

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.